Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide as a Bridge to Mechanical Ventilation in Suspected COVID-19 Respiratory Failure
2020-001656-18Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- Apr 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of nitric oxide in coronavirus disease 2019 (COVID-19) and Acute hypoxaemic respiratory failure (AHRF) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Change in SpO2 following initiation of INOmax. Started Apr 2020; status: terminated.
02
Drugs
nitric oxide
03
Conditions
coronavirus disease 2019 (COVID-19)Acute hypoxaemic respiratory failure (AHRF)
Beyond the preview
Go deeper on 2020-001656-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001656-18.